Rutgers, a clinical trial site for the global Pfizer-BioNTech research study to evaluate the efficacy of its COVID-19 vaccine in children, is looking for participants for a third clinical trial on children ages 6 months to 4 years. “Children can get sick from COVID-19 and can spread the virus to others even if they are asymptomatic. While most children experience mild or no symptoms, some children can get severely ill and could have long-term effects,” said co-lead investigator Simon Li, an associate professor of pediatrics at Rutgers Robert Wood Johnson Medical School. “Maximizing COVID-19 vaccination in all age groups is important to stop the global progression of the disease. Vaccination will also help us feel safer about our children resuming school and daily activities.” The Pediatric Clinical Research Center at Rutgers Robert Wood Johnson Medical School in New Brunswick – the only clinical trial site in New Jersey — is one of the several clinical trial sites for Pfizer-BioNTech’s pediatric study. To read the full story.